Safety and Tolerability of INP105 (Olanzapine by I231 POD® Device) Nasal Spray in Healthy Volunteers - SNAP 101
Clinical trial NCT03624322 · COMPLETED
Trial details
- NCT number
- NCT03624322
- Sponsor
- Impel Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2018-08-05
- Primary completion
- 2018-10-03
- Enrollment
- 38
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.